After the Election, Join Us to Discuss the State of the Biotech Union

Xconomy San Francisco — 

How will the upcoming election affect biotech and healthcare? On December 6 in South San Francisco, Xconomy is gathering scientists, executives, investors, and other thought leaders to dissect the results and look ahead to 2017.

Issues that are crucial to the health and wealth of the nation are in play on Election Day and beyond. The new president and Congress will continue the heated debate over drug pricing and possibly re-examine the Affordable Care Act. The Obama administration’s ambitious precision medicine and cancer “moonshot” initiatives will require renewed political capital—not to mention real capital. Giant technology companies are ever-larger players in healthcare, raising questions about profit, safety, and privacy. And emerging infectious diseases like the Zika virus will require coordination between scientists, legislators, and health officials.

The Bay Area is a great place to hold these conversations, as Californians are being asked to make complicated choices at the ballot. State Proposition 61 for drug price regulation has attracted record dollars and national attention, and San Francisco wants to institute a soda tax to fight obesity.

I’ll be in South San Francisco on Tuesday, Dec. 6 to talk about the hottest national topics with a roster of speakers from the Bay Area and beyond.

Confirmed so far:

Nima Farzan, President and CEO, PaxVax

Laurent Fischer, Chairman and CEO, Tobira Therapeutics

Peter Kuhn, Dean’s Professor of Biological Sciences and Professor of Medicine and Engineering, University of Southern California

Charlotte Hubbert, Partner, Gates Foundation Venture Capital

Melanie Ott, Senior Investigator, Gladstone Institute for Virology and Immunology

Camille Samuels, Partner, Venrock

John Wilbanks, Chief Commons Officer, Sage Bionetworks

If you’re interested in joining us, more details are here.